Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02544152 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
A Phase 2 study, sponsored by Sucampo Pharma Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT02544152 is a Phase 2 study that was terminated before completion, run by Sucampo Pharma Americas. The registered enrollment target is 71 participants.
The verdict
NCT02544152, a Phase 2 study, was terminated before completion, sponsored by Sucampo Pharma Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.
Interventions
- DRUG Placebo
- DRUG Lubiprostone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02544152
The ClinicalTrials.gov registry entry for NCT02544152 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sucampo Pharma Americas, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02544152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02544152 about?
NCT02544152 is a clinical study titled "Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome". A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.
What is the current status of trial NCT02544152?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2015-02. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02544152?
The interventions under investigation include: Placebo (DRUG), Lubiprostone (DRUG).
Who is sponsoring clinical trial NCT02544152?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.